{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:22:02Z","timestamp":1791602522555,"version":"4.3.4"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation Research"],"published-print":{"date-parts":[[2019,10,11]]},"abstract":"<jats:p>Given that cardiovascular safety concerns remain the leading cause of drug attrition at the preclinical drug development stage, the National Center for Toxicological Research of the US Food and Drug Administration hosted a workshop to discuss current gaps and challenges in translating preclinical cardiovascular safety data to humans. This white paper summarizes the topics presented by speakers from academia, industry, and government intended to address the theme of improving cardiotoxicity assessment in drug development. The main conclusion is that to reduce cardiovascular safety liabilities of new therapeutic agents, there is an urgent need to integrate human-relevant platforms\/approaches into drug development. Potential regulatory applications of human-derived cardiomyocytes and future directions in employing human-relevant platforms to fill the gaps and overcome barriers and challenges in preclinical cardiovascular safety assessment were discussed. This paper is intended to serve as an initial step in a public-private collaborative development program for human-relevant cardiotoxicity tools, particularly for cardiotoxicities characterized by contractile dysfunction or structural injury.<\/jats:p>","DOI":"10.1161\/circresaha.119.315378","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T18:00:27Z","timestamp":1570730427000},"page":"855-867","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":73,"title":["Workshop Report"],"prefix":"10.1161","volume":"125","author":[{"given":"Li","family":"Pang","sequence":"first","affiliation":[{"name":"From the Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration (L.P.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Sager","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine (P.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (X.Y.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shi","sequence":"additional","affiliation":[{"name":"Discovery Toxicology, Bristol-Myers Squibb (BMS) Company (H.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Sannajust","sequence":"additional","affiliation":[{"name":"Safety &amp; Exploratory Pharmacology Department, SALAR Division, Merck &amp; Co (F.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Brock","sequence":"additional","affiliation":[{"name":"Investigative Toxicology, Genentech Inc (M.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Wu","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford Cardiovascular Institute (J.C.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najah","family":"Abi-Gerges","sequence":"additional","affiliation":[{"name":"AnaBios Corporation (N.A.-G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Lyn-Cook","sequence":"additional","affiliation":[{"name":"Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration (B.L.-C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Berridge","sequence":"additional","affiliation":[{"name":"Division of the National Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health (B.R.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (N.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","unstructured":"PhRMA. Phrma 2016 biopharmaceutical research industry profile. 2016. https:\/\/www.bms.com\/assets\/bms\/us\/en-us\/pdf\/biopharmaceutical-research-industry-2016-profile.pdf. Accessed September 4 2019."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4609"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfu198"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.11.004"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408449209145324"},{"key":"e_1_3_4_7_2","volume-title":"A Comprehensive Guide to Toxicology In Nonclinical Drug Development","author":"Faqi AS","year":"2016","unstructured":"Faqi, AS. A Comprehensive Guide to Toxicology In Nonclinical Drug Development 2nd ed. Cambridge, Massachusetts: Elsevier Inc; 2016.","edition":"2"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2017.09.006"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2016.06.002"},{"key":"e_1_3_4_10_2","first-page":"55","volume-title":"In: Antitargets: Prediction and Prevention of Drug Side Effects","author":"De Ponti F","year":"2008","unstructured":"De Ponti, F. Pharmacological and regulatory aspects of QT prolongation. Vaz, RJ, Klabunde, T, eds In: Antitargets: Prediction and Prevention of Drug Side Effects. Weinheim, Germany: Wiley-VCH; 2008:55\u201388."},{"key":"e_1_3_4_11_2","unstructured":"FDA drug safety communication. Safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod). December 20 2011. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm284240.htm. Accessed September 4 2019."},{"key":"e_1_3_4_12_2","unstructured":"FDA drug safety communication. Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod) May 14 2012. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-revised-recommendations-cardiovascular-monitoring-and-use-multiple. Accessed September 4 2019."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311743200"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.03.007"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02061.x"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1039\/c6md00539j"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5b00448"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.09.031"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.051"},{"key":"e_1_3_4_20_2","unstructured":"European medicines agency (EMA). EMA recommends avoidance of certain hepatitis C medicines and amiodarone together. April 24 2015. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-avoidance-certain-hepatitis-c-medicines-amiodarone-together. Accessed September 9 2019."},{"key":"e_1_3_4_21_2","unstructured":"Gilead Sciences INC. Gilead \u2013 Solvadi warning letter. March 20 2015. Accessed September 4 2019."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28752"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2016.08.006"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfy110"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.08.079"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw235"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2016.12.003"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2011.08.020"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2013.09.017"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfx082"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2017.05.023"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122634"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2017.12.004"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.10.014"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4087"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2584"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037357"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz326"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.041"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2012.0490"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00481.2015"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.111.973420"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/scrt507"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/scrt406"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.11.055"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.211458"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010617-053110"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfs233"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfm052"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.138.suppl_1.16287"},{"key":"e_1_3_4_51_2","first-page":"791","article-title":"Isolation of single atrial and ventricular cells from the human heart.","volume":"126","author":"Bustamante JO","year":"1982","unstructured":"Bustamante, JO, Watanabe, T, Murphy, DA, McDonald, TF. Isolation of single atrial and ventricular cells from the human heart. Can Med Assoc J. 1982;126:791\u2013793.","journal-title":"Can Med Assoc J"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.85.3.1046"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0008-6363(98)00204-1"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3791\/51116"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2016.05.016"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.01109"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.01073"},{"key":"e_1_3_4_58_2","first-page":"3727","article-title":"A human cardiomyocyte-based platform for the profiling of positive inotropes with potential to treat heart failure [abstract P3492].","volume":"28","author":"Abi-Gerges N IT","year":"2018","unstructured":"Abi-Gerges, N IT, Nguyen, W, Page, G, Nguyen, N, MIller, P, Ghetti, A. A human cardiomyocyte-based platform for the profiling of positive inotropes with potential to treat heart failure [abstract P3492]. Mol Biol Cell. 2018;28:3727.","journal-title":"Mol Biol Cell"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfr158"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/jat.3611"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.06.007"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep44517"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12627"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201210899"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.19406"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.312067"},{"key":"e_1_3_4_67_2","first-page":"158","article-title":"High-throughput analysis of contractile function in adult canine cardiomyocytes via kinetic image cytometry[abstract 1668].","volume":"168","author":"McDonough PM BR","year":"2019","unstructured":"McDonough, PM BR, Ingermanson, R, Azimi, B, Abi-Gerges, N, Miller, P, Price, J. High-throughput analysis of contractile function in adult canine cardiomyocytes via kinetic image cytometry[abstract 1668]. Toxicol Suppl Toxicol Sci. 2019;168:158.","journal-title":"Toxicol Suppl Toxicol Sci"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1649-6"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy134"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2013.09.004"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.314996"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.85.5.1743"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2019.04.001"},{"key":"e_1_3_4_74_2","first-page":"158","article-title":"Assessment of cardiac contractile force modulator using functionally mature human ipsc-derived cardiomyocytes [abstract 1669].","volume":"168","author":"Zhang X YM","year":"2019","unstructured":"Zhang X, YM, Oikonomopoulos, A, Willits, C, Green, K, Abassi, YA. Assessment of cardiac contractile force modulator using functionally mature human ipsc-derived cardiomyocytes [abstract 1669]. Toxicol Suppl Toxicol Sci. 2019;168:158.","journal-title":"Toxicol Suppl Toxicol Sci"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.042"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.03.023"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.307580"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00597"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1259"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06385-8"}],"container-title":["Circulation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCRESAHA.119.315378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:35:02Z","timestamp":1715574902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCRESAHA.119.315378"}},"subtitle":["FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms"],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":79,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,10,11]]}},"alternative-id":["10.1161\/CIRCRESAHA.119.315378"],"URL":"https:\/\/doi.org\/10.1161\/circresaha.119.315378","relation":{},"ISSN":["0009-7330","1524-4571"],"issn-type":[{"value":"0009-7330","type":"print"},{"value":"1524-4571","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"2019-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}